International outsourcing services provider, CROMSOURCE, which works with pharmaceutical, biotech and medical device companies, is providing a series of training modules on the best practices for clinical research regarding specialized conditions, including cystic fibrosis (CF). The course is being organized by the Italian Cystic Fibrosis Society (SIFC) and is taking place until…

A recent study from Israel found that three or more patients with Cystic Fibrosis in one family may be a risk for more severe disease and poor prognosis. The study entitled “Several siblings with Cystic Fibrosis as a risk factor for poor outcome” was recently…

Peter Barry from the Manchester Adult Cystic Fibrosis Centre at the University Hospital of South Manchester and Alex Horsley from the Institute of Inflammation and Repair, Education and Research Centre at the University of Manchester recently reported the case of a 20-year-old man with CF. The report, entitled “…

Vertex Pharmaceuticals, Inc., a pharmaceutical company known for discovering, developing and commercializing novel medicines for serious diseases with largely unmet clinical needs such as cystic fibrosis (CF), recently revealed the company’s corporate outlook for the year 2015, prior to their scheduled presentation at the highly-anticipated 33rd J.P. Morgan Healthcare…

A new editorial entitled “Comparing cystic fibrosis outcomes across the pond” was recently published online in the journal Thorax. In the editorial, David C Taylor-Robinson from the Department of Public Health and Policy, at the University of Liverpool in the United Kingdom along with colleagues discuss…

Norwood, Massachusetts-based, Corbus Pharmaceuticals Holdings, Inc., recently announced their Chief Executive Officer, Yuval Cohen, Ph.D., has been invited to present at two upcoming investor conferences. Both presentations will highlight and discuss Corbus’ lead pipeline therapeutic for serious inflammatory and fibrotic conditions, Resunab™, which has as its active ingredient, ajulemic…

 KaloBios Pharmaceuticals, Inc. recently announced data on a Phase 2 randomized double-blind, placebo-controlled trial of KB001-A, an anti-PcrV monoclonal antibody (mAb) fragment, to be used as treatment for Pseudomonas aeruginosa (Pa) lung infections in subjects with cystic fibrosis (CF). The KB001-A trial enrolled 182 patients with CF who had their lungs…

Protalix BioTherapeutics, Inc., an Israeli pharmaceutical company known for its proprietary, US Food and Drug Administration-approved, plant-based enzyme taliglucerase alfa for Gaucher disease, recently announced their new company strategy for accelerated growth. The Company has begun reinforcing their R&D efforts and laying new groundwork for a renewed focus on…

In a report published this week by SPIE — an international not-for-profit society serving more than 256,000 constituents from approximately 155 countries advancing an interdisciplinary approach to the science and application of light — entitled “Laser trapping to show the effects of bacterial arrangement on biofilm infection” (30 December 2014,…